PROJECT 2 will explore issues related to the progression kinetics of a primary hepatic tumor (hepatocellular carcinoma), developing a broader understanding of the biophysical barriers involved in the Radio Frequency (RF) based thermal therapy and MRI/CT imaging of HCC employing gold nanoparticles (AuNPs) and fullerene particles (nano-C60). These will include the transport of the nanoparticles towards the lesion;the sufficient and specific accumulation of the nanoparticles within the tumor cells;the heat generation upon RF activation and the heat transfer to the surrounding tissue. This goal will be achieved through an integrated process where in-vitro testing and in-vivo studies are combined with predictive in-silico mathematical models. The Team leading this project brings together a multidisciplinary expertise and is composed of Dr. Steven A. Curley and Dr. Lon Wilson as co-leaders and Dr. Paul Cherukuri as co-investigator. Dr. Curley is a Professor of Surgical Oncology at the MDACC and Professor of Mechanical Engineering and Materials Science at Rice University. Dr. Wilson has been a Professor of Chemistry at Rice University for over 30 years. He has held NSF and NIH-sponsored fellowships and has published over 150 manuscripts and book chapters. Dr. Cherukuri is an Assistant Professor within the Surgical Oncology and Experimental Therapeutics Department of the MDACC and received his Ph.D. in physical chemistry under the supervision of Nobel Laureate, Prof. Richard E. Smalley and Prof. Bruce Weisman at Rice University. Dr. Cherukuri's research focused on the synthesis, characterization and development of nanoscale diagnostic and therapeutic materials for the treatment of cancer and heart disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA143837-07
Application #
8755651
Study Section
Special Emphasis Panel (ZCA1-SRLB-9)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
7
Fiscal Year
2014
Total Cost
$163,685
Indirect Cost
$36,592
Name
Methodist Hospital Research Institute
Department
Type
DUNS #
185641052
City
Houston
State
TX
Country
United States
Zip Code
77030
Kojic, M; Milosevic, M; Kojic, N et al. (2018) Mass release curves as the constitutive curves for modeling diffusive transport within biological tissue. Comput Biol Med 92:156-167
Koay, Eugene J; Lee, Yeonju; Cristini, Vittorio et al. (2018) A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24:5883-5894
Mu, Chaofeng; Wu, Xiaoyan; Zhou, Xinyu et al. (2018) Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer. Clin Cancer Res 24:4900-4912
Amer, Ahmed M; Zaid, Mohamed; Chaudhury, Baishali et al. (2018) Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer 124:1701-1709
Koay, Eugene J; Hall, William; Park, Peter C et al. (2018) The role of imaging in the clinical practice of radiation oncology for pancreatic cancer. Abdom Radiol (NY) 43:393-403
Martinez, Jonathan O; Molinaro, Roberto; Hartman, Kelly A et al. (2018) Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery. Theranostics 8:1131-1145
Mai, Junhua; Li, Xin; Zhang, Guodong et al. (2018) DNA Thioaptamer with Homing Specificity to Lymphoma Bone Marrow Involvement. Mol Pharm 15:1814-1825
Krzykawska-Serda, Martyna; Agha, Mahdi S; Ho, Jason Chak-Shing et al. (2018) Chemotherapy and Radiofrequency-Induced Mild Hyperthermia Combined Treatment of Orthotopic Pancreatic Ductal Adenocarcinoma Xenografts. Transl Oncol 11:664-671
Tang, Chad; Hobbs, Brian; Amer, Ahmed et al. (2018) Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci Rep 8:1922
Wang, Feng; Xia, Xiaojun; Yang, Chunying et al. (2018) SMAD4 Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy through Promotion of Autophagy. Clin Cancer Res 24:3176-3185

Showing the most recent 10 out of 255 publications